Nbryo HQ
Nbryo HQ BBQ & Mini Golf
It was a great opportunity to fire up the barbie at HQ and enjoy a delicious beef-rich lunch, followed by a speed round of mini ...
February 25, 2026
The round received further support from Tenacious Ventures, AgriZeroNZ, and Fiteni, who have demonstrated ongoing confidence in Nbryo by subscribing again in this second close. Their commitment, alongside new and returning investors, enabled Nbryo to meet its minimum AUD$8 million target for this second close, and achieve an overall total of AUD$18 million raised.
We are delighted to welcome the Gates Foundation as a new equity investor in Nbryo.
Their involvement opens doors and will help us deliver on our mission, said Paul Niven, CEO of Nbryo Pty Ltd.
This second close strengthens Nbryo’s ability to execute its strategy, expand its proprietary IVF and embryo transfer technology platform, and accelerate the delivery of next generation solutions for cattle producers worldwide. The company’s integrated approach, combining biotechnology with digital tools, continues to set new standards for efficiency, scalability, and genetic gain in the beef and dairy sectors.
Nbryo extends its sincere appreciation to all investors who participated in this second close, as well as those who contributed to the September close. The company also acknowledges the ongoing support from broader stakeholders, including employees, grant funders, commercial partners, and customers.
Special thanks go to the Capital Raising team, the board, and the executive leadership whose dedication and expertise ensured the successful completion of this milestone.
Nbryo is an Australian agri-biotech company developing next-generation solutions in bovine reproductive technologies. Its integrated IVF technology platform combines biotechnology with digital tools to deliver scalable, efficient, and high-quality outcomes for cattle producers worldwide.
www.nbryo.com
Paul Niven
CEO
+61 (0) 481 814496
